Advertisement

Breast Cancer Research and Treatment

, Volume 154, Issue 1, pp 57–62 | Cite as

Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis

  • Alimujiang Wushou
  • Yi-Zhou Jiang
  • Jing Hou
  • Yi-Rong Liu
  • Xiao-Mao Guo
  • Zhi-Ming Shao
Preclinical Study

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease with highest loco-regional recurrence among breast cancer subtypes. Radiotherapy is indispensable for TNBC loco-regional control. However, intrinsic radiosensitivity differences exist in TNBC patients and RT is still prescribed mainly based on conventional clinicopathologic features of patients without considering the differences. The purpose of the present study is to develop and validate a TNBC radiosensitive gene signature (RSGS) and to guide therapeutic decisions. In this study, we compared transcriptome profiles of 12 locally recurrent TNBCs to 20 non-locally recurrent TNBCs treated with surgery radio-chemotherapy and developed a seven-gene RSGS and a simplified three-gene RSGS by using pathway analysis, univariate Cox proportional hazards regression model and rank-based linear algorithm. They were validated by using transcriptome profiles of 166 TNBC patients. Two gene signatures specifically identified a radiosensitive population that had an improved recurrence-free survival in patients treated with surgery radio-chemotherapy (Radiosensitive patients vs radioresistant patients, for seven-gene RSGS: P = 0.024, HR = 0.35, 95 %CI 0.14–0.87 and for three-gene RSGS: P = 0.035, HR = 0.38, 95 %CI 0.15–0.94). In contrast, there was no significant difference in outcome between predicted radiosensitive and radioresistant patients that treated with other treatment modality. RSGSs provide a useful tool for identification of radiosensitive/radioresistant TNBC patients and they could lead to a better selection of patients for RT protocols.

Keywords

Triple-negative breast cancer Transcriptome analysis Radiosensitive gene signature 

Notes

Acknowledgments

This study was supported by Project Funded by China Postdoctoral Science Foundation (2015M571493) and grants from the National Natural Science Foundation of China (81372848, 81370075). We are grateful to Dr. Kamila Abulimiti (MD) from Strayer University (USA) for checking the English of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

10549_2015_3611_MOESM1_ESM.tif (664 kb)
Supplementary material 1 (TIFF 663 kb)
10549_2015_3611_MOESM2_ESM.tif (454 kb)
Supplementary material 2 (TIFF 453 kb)
10549_2015_3611_MOESM3_ESM.doc (50 kb)
Supplementary material 3 (DOC 49 kb)
10549_2015_3611_MOESM4_ESM.doc (135 kb)
Supplementary material 4 (DOC 135 kb)
10549_2015_3611_MOESM5_ESM.doc (50 kb)
Supplementary material 5 (DOC 49 kb)

References

  1. 1.
    DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA. CA Cancer J Clin 64(1):52–62CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA. CA Cancer J Clin 65(1):5–29CrossRefPubMedGoogle Scholar
  3. 3.
    Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948CrossRefPubMedGoogle Scholar
  4. 4.
    Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115(2):325–333. doi: 10.1007/s10549-008-0096-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399PubMedGoogle Scholar
  6. 6.
    Group EBCTC (2006) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106Google Scholar
  7. 7.
    Chen X, Yu X, Chen J, Yang Z, Shao Z, Zhang Z, Guo X, Feng Y (2013) Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist 18(2):141–147. doi: 10.1634/theoncologist.2012-0233 PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29(21):2852–2858CrossRefPubMedGoogle Scholar
  9. 9.
    Moran MS (2015) Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol 16(3):e113–e122. doi: 10.1016/s1470-2045(14)71104-0 CrossRefPubMedGoogle Scholar
  10. 10.
    Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF (2009) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75(2):489–496. doi: 10.1016/j.ijrobp.2009.06.014 PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Eschrich S, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Torres-Roca JF (2009) Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75(2):497–505. doi: 10.1016/j.ijrobp.2009.05.056 PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    van’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536CrossRefGoogle Scholar
  13. 13.
    Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8(8):R157PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679CrossRefPubMedGoogle Scholar
  15. 15.
    Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12(5):R85PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY (2012) Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS ONE 7(9):e45831. doi: 10.1371/journal.pone.0045831 PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH, Harris EE, Bergh J, Torres-Roca JF (2012) Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res 18(18):5134–5143. doi: 10.1158/1078-0432.CCR-12-0891 PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4(4):309–314CrossRefPubMedGoogle Scholar
  19. 19.
    Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 20(6):701–714PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Chen Q, Zhang XH-F, Massagué J (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20(4):538–549PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer CenterFudan UniversityShanghaiChina
  2. 2.Department of Radiation Oncology, Fudan University Shanghai Cancer CenterFudan UniversityShanghaiChina
  3. 3.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations